Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2019) 7 OC9 | DOI: 10.1530/boneabs.7.OC9

ICCBH2019 Oral Communications (1) (27 abstracts)

Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial

Leanne M Ward 1 , Nathalie Alos 2 , David A Cabral 3 , Celia Rodd 4 , Anne Marie Sbrocchi 5 , Raja Padidela 6 , Nick Shaw 7 , Mikhail Kostik 8 , Ekaterina Alexeeva 9 , Kebashni Thandrayen 10 , Paul Aftring 11 , Anup Choudhury 12 , Gangadhar Sunkara 12 , Sarfaraz Sayyed 12 & Craig F. Munns 13

1Children’s Hospital of Eastern Ontario, Ontario, Canada; 2Sainte Justine Hospital, Montreal, Canada; 3British Columbia Children’s Hospital, Vancouver, Canada; 4University of Manitoba, Winnipeg, Canada; 5Montreal Children’s Hospital, Montreal, Canada; 6Royal Manchester Children’s Hospital, Manchester, UK; 7Birmingham Children’s Hospital, Birmingham, UK; 8Saint-Petersburg State Pediatric Medical University of the MoH, Saint-Petersburg, Russia; 9Federal State Budget Research Institution, Research Centre of Children’s Health, Russia; 10Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 11Novartis Pharmaceuticals Corporation, NJ; 12Novartis Pharmaceuticals Pvt. Ltd, Hyderabad, India; 13Children’s Hospital at Westmead, Westmead, Australia.

Objectives: We evaluated the efficacy and safety of intravenous zoledronic acid (IV ZA) in children with glucocorticoid-induced osteoporosis (GIOP) through a randomized, placebo (PBO)-controlled trial.

Methods: In this multi-national Phase 3 trial (NCT00799266), children 5–17 years of age with GIOP and low-trauma vertebral fractures (VF) were randomized 1:1 to IV ZA 0.05 mg/kg or IV PBO every six months for one year. Changes in lumbar spine areal bone mineral density Z-scores (BMDZ, primary outcome) and the frequency of new low-trauma VF were assessed centrally with treatment blinding. Adverse events (AEs) and serious AEs (SAEs) were recorded.

Results: Thirty-four children (38% with Duchenne, 35% rheumatic conditions, 27% Crohn’s disease, mean age 12.6±3.4 years, 68% boys) were enrolled in the study (ZA, n=18; PBO, n=16). Thirty-three and 30 children completed 6 and 12 months of the trial, respectively; two children (ZA) withdrew for logistical reasons (school commitments, participation in another trial), and two withdrew after incident fractures (clavicle, ZA; new VF, PBO). Data are presented on 33 children with at least one follow-up visit. The mean ± standard deviation change in spine BMDZ over 1 year was −2.1±0.8 to −1.5±1.0 on ZA compared with −2.4±0.9 to −2.3±1.0 on PBO, least squares (LS) mean between-group BMDZ difference 0.414, 95% confidence interval 0.022, 0.806; P=0.039. Two children on PBO had new low-trauma VF in previously normal vertebrae. Eight-three percent of children had AEs on ZA vs 75% on PBO. Sixty-seven percent (ZA) vs 25% (PBO) of AEs occurred within 10 days following the first infusion, largely due to transient post-dose gastrointestinal complaints. Five children on ZA and one child on PBO had SAEs; 4/5 children on ZA had gastrointestinal SAEs, and two of these children had SAEs within 10 days following ZA (transient, one with hypocalcemia, one with acute phase reaction symptoms). There were no deaths, nor treatment discontinuations due to ZA.

Conclusions: Over one year, spine BMDZ in children with GIOP significantly increased on ZA compared with PBO. AEs and SAEs were consistent with the known, transient side effects of ZA.

Disclosure: Dr. Ward has been a consultant to Novartis Pharmaceuticals. The other co-authors have nothing to declare.

Volume 7

9th International Conference on Children's Bone Health


Browse other volumes

Article tools

My recent searches

No recent searches.